Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiri Minarik

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Journal of Hematology & Oncology|April 5, 2018
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE studyMeletios Dimopoulos, Michael Wang, Vladimir Maisnar, et al.
European Journal of Haematology|May 5, 2017
CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapyJiri Minarik, Martin Novak, Patrik Flodr, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|November 7, 2018
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" populationJiri Minarik, Ludek Pour, Vladimir Maisnar, et al.
Gigascience|March 9, 2026
Multiplatform comparisons and annotation of structural variants highlight the utility of the T2T reference genome in human diagnosticsJakub Savara, Tomas Novosad, Petr Gajdos, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|February 5, 2005
Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapyTomas Buchler, Marta Krejci, Adam Svobodnik, et al.
Oncotarget|October 21, 2017
Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myelomaPetra Schneiderova, Tomas Pika, Petr Gajdos, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|February 28, 2014
Analysis of thymidine kinase serum levels by novel method DiviTum in multiple myeloma and monoclonal gammopathy of undetermined significance - comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CTJaroslav Bacovsky, Miroslav Myslivecek, Jiri Minarik, et al.
American Journal of Hematology|May 13, 2016
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)Xavier Leleu, Evangelos Terpos, Ramón García Sanz, et al.
Journal of Translational Medicine|March 26, 2013
Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myelomaElena Dementyeva, Fedor Kryukov, Lenka Kubiczkova, et al.
Molecular Medicine Reports|August 31, 2022
The epigenetic impact of suberohydroxamic acid and 5‑Aza‑2'‑deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL‑6 expressionKaterina Smesny Trtkova, Petra Luzna, Denisa Weiser Drozdkova, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Journal of Hematology & Oncology|April 5, 2018
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE studyMeletios Dimopoulos, Michael Wang, Vladimir Maisnar, et al.
European Journal of Haematology|May 5, 2017
CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapyJiri Minarik, Martin Novak, Patrik Flodr, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|November 7, 2018
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" populationJiri Minarik, Ludek Pour, Vladimir Maisnar, et al.
Gigascience|March 9, 2026
Multiplatform comparisons and annotation of structural variants highlight the utility of the T2T reference genome in human diagnosticsJakub Savara, Tomas Novosad, Petr Gajdos, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|February 5, 2005
Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapyTomas Buchler, Marta Krejci, Adam Svobodnik, et al.
Oncotarget|October 21, 2017
Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myelomaPetra Schneiderova, Tomas Pika, Petr Gajdos, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|February 28, 2014
Analysis of thymidine kinase serum levels by novel method DiviTum in multiple myeloma and monoclonal gammopathy of undetermined significance - comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CTJaroslav Bacovsky, Miroslav Myslivecek, Jiri Minarik, et al.
American Journal of Hematology|May 13, 2016
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)Xavier Leleu, Evangelos Terpos, Ramón García Sanz, et al.
Journal of Translational Medicine|March 26, 2013
Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myelomaElena Dementyeva, Fedor Kryukov, Lenka Kubiczkova, et al.
Molecular Medicine Reports|August 31, 2022
The epigenetic impact of suberohydroxamic acid and 5‑Aza‑2'‑deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL‑6 expressionKaterina Smesny Trtkova, Petra Luzna, Denisa Weiser Drozdkova, et al.
Pageof 6